177 related articles for article (PubMed ID: 24387139)
1. Long-term follow-up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab.
Koudriavtseva T; Sbardella E; Trento E; Bordignon V; D'Agosto G; Cordiali-Fei P
Clin Exp Immunol; 2014 Jun; 176(3):320-6. PubMed ID: 24387139
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.
Harrer A; Pilz G; Einhaeupl M; Oppermann K; Hitzl W; Wipfler P; Sellner J; Golaszewski S; Afazel S; Haschke-Becher E; Trinka E; Kraus J
PLoS One; 2012; 7(2):e31784. PubMed ID: 22363732
[TBL] [Abstract][Full Text] [Related]
3. Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
Plavina T; Muralidharan KK; Kuesters G; Mikol D; Evans K; Subramanyam M; Nestorov I; Chen Y; Dong Q; Ho PR; Amarante D; Adams A; De Sèze J; Fox R; Gold R; Jeffery D; Kappos L; Montalban X; Weinstock-Guttman B; Hartung HP; Cree BAC
Neurology; 2017 Oct; 89(15):1584-1593. PubMed ID: 28916537
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric flow cytometric analysis of whole blood reveals changes in minor lymphocyte subpopulations of multiple sclerosis patients.
Teniente-Serra A; Grau-López L; Mansilla MJ; Fernández-Sanmartín M; Ester Condins A; Ramo-Tello C; Martínez-Cáceres E
Autoimmunity; 2016 Jun; 49(4):219-28. PubMed ID: 26829210
[TBL] [Abstract][Full Text] [Related]
5. Analysis of CD4+ CD8+ double-positive T cells in blood, cerebrospinal fluid and multiple sclerosis lesions.
Waschbisch A; Sammet L; Schröder S; Lee DH; Barrantes-Freer A; Stadelmann C; Linker RA
Clin Exp Immunol; 2014 Aug; 177(2):404-11. PubMed ID: 24730443
[TBL] [Abstract][Full Text] [Related]
6. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis.
de Andrés C; Teijeiro R; Alonso B; Sánchez-Madrid F; Martínez ML; Guzmán de Villoria J; Fernández-Cruz E; Sánchez-Ramón S
PLoS One; 2012; 7(4):e34103. PubMed ID: 22496780
[TBL] [Abstract][Full Text] [Related]
7. High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis.
Harrer A; Pilz G; Wipfler P; Oppermann K; Sellner J; Hitzl W; Haschke-Becher E; Afazel S; Rispens T; van der Kleij D; Trinka E; Kraus J
Clin Exp Immunol; 2015 Jun; 180(3):383-92. PubMed ID: 25603898
[TBL] [Abstract][Full Text] [Related]
8. CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.
Carotenuto A; Scalia G; Ausiello F; Moccia M; Russo CV; Saccà F; De Rosa A; Criscuolo C; Del Vecchio L; Brescia Morra V; Lanzillo R
J Neuroimmunol; 2017 Aug; 309():47-50. PubMed ID: 28601287
[TBL] [Abstract][Full Text] [Related]
9. Real-World Lab Data in Natalizumab Treated Multiple Sclerosis Patients Up to 6 Years Long-Term Follow Up.
Kaufmann M; Haase R; Proschmann U; Ziemssen T; Akgün K
Front Neurol; 2018; 9():1071. PubMed ID: 30581413
[TBL] [Abstract][Full Text] [Related]
10. Natalizumab therapy for highly active pediatric multiple sclerosis.
Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
[TBL] [Abstract][Full Text] [Related]
11. Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.
Wipfler P; Oppermann K; Pilz G; Afazel S; Haschke-Becher E; Harrer A; Huemer M; Kunz A; Golaszewski S; Staffen W; Ladurner G; Kraus J
Mult Scler; 2011 Jan; 17(1):16-23. PubMed ID: 20937631
[TBL] [Abstract][Full Text] [Related]
12. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Stüve O; Marra CM; Bar-Or A; Niino M; Cravens PD; Cepok S; Frohman EM; Phillips JT; Arendt G; Jerome KR; Cook L; Grand'Maison F; Hemmer B; Monson NL; Racke MK
Arch Neurol; 2006 Oct; 63(10):1383-7. PubMed ID: 17030653
[TBL] [Abstract][Full Text] [Related]
13. Increased B cell and cytotoxic NK cell proportions and increased T cell responsiveness in blood of natalizumab-treated multiple sclerosis patients.
Mellergård J; Edström M; Jenmalm MC; Dahle C; Vrethem M; Ernerudh J
PLoS One; 2013; 8(12):e81685. PubMed ID: 24312575
[TBL] [Abstract][Full Text] [Related]
14. The frequency of occurrence of atypical lymphocytes in peripheral blood smears of natalizumab-treated patients with multiple sclerosis.
Robier C; Amouzadeh-Ghadikolai O; Bregant C; Diez J; Melinz K; Quehenberger F; Quasthoff S
Int J Lab Hematol; 2017 Oct; 39(5):469-474. PubMed ID: 28481019
[TBL] [Abstract][Full Text] [Related]
15. Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis.
Börnsen L; Christensen JR; Ratzer R; Oturai AB; Sørensen PS; Søndergaard HB; Sellebjerg F
PLoS One; 2012; 7(11):e47578. PubMed ID: 23226199
[TBL] [Abstract][Full Text] [Related]
16. Immune cells after prolonged Natalizumab therapy: implications for effectiveness and safety.
Marousi S; Karkanis I; Kalamatas T; Travasarou M; Paterakis G; Karageorgiou CE
Acta Neurol Scand; 2013 Jul; 128(1):e1-5. PubMed ID: 23311457
[TBL] [Abstract][Full Text] [Related]
17. JC virus detection and JC virus-specific immunity in natalizumab-treated multiple sclerosis patients.
Mancuso R; Saresella M; Hernis A; Marventano I; Ricci C; Agostini S; Rovaris M; Caputo D; Clerici M
J Transl Med; 2012 Dec; 10():248. PubMed ID: 23232085
[TBL] [Abstract][Full Text] [Related]
18. Immunological markers of optimal response to natalizumab in multiple sclerosis.
Villar LM; García-Sánchez MI; Costa-Frossard L; Espiño M; Roldán E; Páramo D; Lucas M; Izquierdo G; Álvarez-Cermeño JC
Arch Neurol; 2012 Feb; 69(2):191-7. PubMed ID: 22332187
[TBL] [Abstract][Full Text] [Related]
19. No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.
Rinaldi L; Rinaldi F; Perini P; Calabrese M; Seppi D; Grossi P; Mattisi I; Barzon L; Mengoli C; Sanzari M; Palú G; Gallo P
J Neurol Neurosurg Psychiatry; 2010 Dec; 81(12):1345-50. PubMed ID: 20547618
[TBL] [Abstract][Full Text] [Related]
20. Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis.
Sellner J; Koczi W; Harrer A; Oppermann K; Obregon-Castrillo E; Pilz G; Wipfler P; Afazel S; Haschke-Becher E; Trinka E; Kraus J
Clin Exp Immunol; 2013 Sep; 173(3):381-9. PubMed ID: 23611040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
